Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Chubb
Daiichi Sankyo
Deloitte
Merck
Argus Health
Moodys
Fuji
Fish and Richardson

Generated: April 25, 2018

DrugPatentWatch Database Preview

ULORIC Drug Profile

« Back to Dashboard

When do Uloric patents expire, and what generic alternatives are available?

Uloric is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and five patent family members in thirty-five countries.

The generic ingredient in ULORIC is febuxostat. There are twenty-five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the febuxostat profile page.
Summary for ULORIC
Drug patent expirations by year for ULORIC
Pharmacology for ULORIC
Medical Subject Heading (MeSH) Categories for ULORIC
Synonyms for ULORIC
060F537
101V0R1N2E
111GE013
144060-53-7
2-?[3-?CYANO-?4-?(2-?METHYLPROPOXY)PHENYL]-?4-?METHYL-?5-?THIAZOLECARBOXYLIC ACID
2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid
2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID
2-(3-cyano-4-isobutoxy-phenyl)-4-methyl-thiazole-5-carboxylic acid
2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid
2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid
2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid
2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-5-thiazolecarboxylic acid
2-[3-Cyano-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid
5-Thiazolecarboxylic acid, 2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methyl-
5-Thiazolecarboxylic acid, 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-
AB0005158
AB01274796_02
AB01274796_03
AB01274796-01
AB2000143
ABP000399
AC-425
AC1L33UC
ACT06289
Adenuric
Adenuric, Uloric , Febutaz
AK-83533
AKOS015841695
AM20090760
AN-608
ANW-46040
API0004334
BB_SC-12106
BC220527
BCP9000679
BCPP000233
BDBM50320491
BQSJTQLCZDPROO-UHFFFAOYSA-N
BS-1018
C-23827
C16H16N2O3S
CAS-144060-53-7
CC-28363
CCG-213303
CHEBI:31596
CHEMBL1164729
CS-0403
CTK8B4748
D01206
D0A5SE
DB04854
DR001370
DSSTox_CID_28576
DSSTox_GSID_48650
DSSTox_RID_82848
DTXSID8048650
EN300-122360
F0847
FBX
FC0017
FD7322
Febric
februxostat
Feburic
Feburic (TN)
Febuxostat
Febuxostat (JAN/USAN/INN)
Febuxostat (Uloric)
Febuxostat [USAN:INN:BAN]
Febuxostat [USAN]
Febuxostat, >=98% (HPLC)
Febuxostat,Uloric, TMX-67
Febuxostat;
Febuxostat(TEI 6720)
Febuxostat(Uloric) /
Febuxostatum
FT-0081351
FT-0601639
GTPL6817
HE111675
HMS3264C20
HMS3655C03
HY-14268
J10392
KS-00000G8Y
LS-173202
MCULE-6974079178
MFCD00871598
MLS004774136
MLS006011568
MolPort-005-940-740
MX-67
NCGC00182059-02
NCGC00182059-03
NSC-758874
NSC758874
PB33929
Pharmakon1600-01504286
Q-100164
Q-4339
RP17652
RTC-070914
S033
S1547
SC-20178
SCHEMBL249339
SMR002529566
SR-01000940023
SR-01000940023-2
ST24027508
TC-070914
TEI
Tei 6720
Tei-6720
TMX 67
TMX-67
TMX-67, Adenuric, Uloric, Febuxostat
TMX-67;Adenuric;Uloric
Tox21_113004
Tox21_113004_1
Uloric (TN)
UNII-101V0R1N2E
Z1550648761
ZINC5423
Zurig

US Patents and Regulatory Information for ULORIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ULORIC
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 40 mg and 80 mg ➤ Subscribe 2013-02-13

Supplementary Protection Certificates for ULORIC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0140037 00152 Estonia ➤ Try a Free Trial PRODUCT NAME: FEBUKSOSTAAT;REG NO/DATE: EU/1/08/447 23.04.2008
C/GB10/019 United Kingdom ➤ Try a Free Trial SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB10/019 GRANTED TO TEIJIN LIMITED IN RESPECT OF THE PRODUCT FEBUXOSTAT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6408 DATED 14/03/2012 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22/04/2023.
00447 Netherlands ➤ Try a Free Trial PRODUCT NAME: FEBUXOSTAT; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421
682 Luxembourg ➤ Try a Free Trial 91682, EXPIRES: 20230421
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Boehringer Ingelheim
Chinese Patent Office
Baxter
Johnson and Johnson
Argus Health
Express Scripts
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.